Boston Scientific (BSX) Revenue — Quarter Ended Dec 31, 2025
Revenue increased for the quarter, continuing the upward trajectory observed throughout the year. The growth rate, while still positive, moderated compared to the prior sequential quarter.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue increased for the quarter, continuing the upward trajectory observed throughout the year. The growth rate, while still positive, moderated compared to the prior sequential quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$5.3B
Revenue reported for this quarter.
Quarter-over-quarter
+4.4%
Change from the immediately preceding quarter.
Year-over-year
+15.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$20.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $4.7B | +20.9% |
| Jun 30, 2025 | $5.1B | +22.8% |
| Sep 30, 2025 | $5.1B | +20.3% |
| Dec 31, 2025 | $5.3B | +15.9% |
Revenue performance
The reported revenue rose relative to both the immediately preceding quarter and the same period a year earlier, though the sequential gain was more modest than the year-over-year improvement.
Quarterly comparison
Compared to the prior quarter, revenue expanded at a slower pace. Against the same quarter last year, revenue showed a larger increase.
What to watch
Monitor whether the sequential revenue growth rate stabilizes or trends lower in future quarters.